BR102019026681A2 - PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE - Google Patents

PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE Download PDF

Info

Publication number
BR102019026681A2
BR102019026681A2 BR102019026681-3A BR102019026681A BR102019026681A2 BR 102019026681 A2 BR102019026681 A2 BR 102019026681A2 BR 102019026681 A BR102019026681 A BR 102019026681A BR 102019026681 A2 BR102019026681 A2 BR 102019026681A2
Authority
BR
Brazil
Prior art keywords
silver
silver nitrate
pharmaceutical composition
composition based
ppm
Prior art date
Application number
BR102019026681-3A
Other languages
Portuguese (pt)
Inventor
Jader Ayub Alves Cardoso
Original Assignee
Jader Ayub Alves Cardoso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jader Ayub Alves Cardoso filed Critical Jader Ayub Alves Cardoso
Priority to BR102019026681-3A priority Critical patent/BR102019026681A2/en
Publication of BR102019026681A2 publication Critical patent/BR102019026681A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/02Elements
    • C08K3/08Metals

Abstract

composição farmacêutica à base de nitrato de prata. é descrita uma composição farmacêutica que compreende a diluição de 1 a 1000 ppm de nitrato de prata, com tamanho de partícula entre 1nm a 1µm, provendo uma solução coloidal para administração oral a humanos e animais, com potencial ação antiviral, que pode ser administrado isoladamente ou associado a antibióticos, atacando uma gama maior de microrganismos em virtude de acometer qualquer lugar da célula, ao contrário dos antibióticos que atacam um determinado sítio da bactéria e não gerando cepas resistentes.pharmaceutical composition based on silver nitrate. a pharmaceutical composition is described which comprises a dilution of 1 to 1000 ppm of silver nitrate, with particle size between 1nm to 1µm, providing a colloidal solution for oral administration to humans and animals, with potential antiviral action, which can be administered alone or associated with antibiotics, attacking a wider range of microorganisms because they affect any place in the cell, unlike antibiotics that attack a specific site in the bacteria and do not generate resistant strains.

Description

COMPOSIÇÃO FARMACÊUTICA À BASE DE NITRATO DE PRATAPHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE CAMPO DA INVENÇÃOFIELD OF THE INVENTION

[01] A presente patente de invenção descreve uma composição farmacêutica à base de nitrato de prata, na forma líquida, administrada de forma oral a humanos e animais, com potencial ação antiviral acentuada quando administrada em conjunto com antibióticos ou não, modificando as estruturas celulares e prejudicando os processos bacterianos, podendo ocasionar sua morte celular.[01] The present patent describes a pharmaceutical composition based on silver nitrate, in liquid form, administered orally to humans and animals, with a potential marked antiviral action when administered together with antibiotics or not, modifying cell structures and harming bacterial processes, which can lead to cell death.

ANTECEDENTES DA INVENÇÃOBACKGROUND OF THE INVENTION

[02] Desde a antiguidade, os humanos jogam moedas em fontes de água, como poços e fontes. Uma teoria diz as propriedades antibacterianas da prata já eram conhecidas, e isso era feito para tornar a água mais segura para beber. Hoje, existem cada vez mais evidências de que a prata também pode ter vários outros benefícios à saúde, principalmente na forma coloidal, uma solução na qual as nanopartículas de prata ficam suspensas na água.[02] Since ancient times, humans have thrown coins into water sources such as wells and fountains. One theory says the antibacterial properties of silver were already known, and this was done to make the water safer to drink. Today, there is growing evidence that silver can also have a number of other health benefits, particularly in colloidal form, a solution in which silver nanoparticles are suspended in water.

[03] A prata coloidal tem se tornado cada vez mais popular com o passar das décadas, mas os benefícios à saúde que a prata traz têm sido utilizados por milênios, e acredita-se que sua primeira aplicação com intuitos medicinais foi há cerca de 2.000 anos - acredita-se que Hipocrates utilizou a prata para curar úlceras na pele e ferimentos. Durante o século IV, ela foi usada pelos egípcios e, em 980 D.C., Avicena a utilizou para purificar o sangue e tratar palpitações cardíacas e mau hálito. No século XIV, Konrad von Megenberg relatou, na obra Livro da Natureza, que os restos de prata, quando aplicados de forma tópica, podem ser usados para tratar sarnas e hemorroidas com sangramento.[03] Colloidal silver has become increasingly popular over the decades, but the health benefits that silver brings have been used for millennia, and its first application for medicinal purposes is believed to have been around 2,000 years - Hippocrates is believed to have used silver to heal skin ulcers and wounds. During the 4th century it was used by the Egyptians, and in 980 AD Avicenna used it to purify blood and treat heart palpitations and bad breath. In the 14th century, Konrad von Megenberg reported, in The Book of Nature, that the silver remains, when applied topically, can be used to treat scabies and bleeding hemorrhoids.

[04] Hahnemann (1755-1843), o criador da medicina homeopática, também utilizou a prata para tratar problemas médicos, incluindo o nitrato de prata para ajudar a conter sangramentos. O nitrato de prata ainda é usado hoje por médicos, para parar um sangramento leve depois de um procedimento dermatológico.[04] Hahnemann (1755-1843), the creator of homeopathic medicine, also used silver to treat medical conditions, including silver nitrate to help stop bleeding. Silver nitrate is still used today by doctors to stop light bleeding after a dermatological procedure.

[05] A prata é um metal conhecido pela sua ampla atividade biocida contra bactérias Gram-positivas e Gram-negativas, fungos, protozoários e certos vírus, incluindo espécies resistentes a antibióticos é a prata. Segundo Monteiro et ai. (MONTEIRO, D. R. et al. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. International Journal of Antimicrobial Agents, v. 34, p. 103-110, 2009.), a prata pode ser usada na redução de infecções em áreas queimadas, para prevenir a colonização bactericida sobre dispositivos médicos, assim como nas fábricas têxteis e para o tratamento de água. A prata, como um agente antisséptico, tem sido eficaz em uma variedade de materiais, incluindo vidro, titânio e polímeros.[05] Silver is a metal known for its broad biocidal activity against Gram-positive and Gram-negative bacteria, fungi, protozoa, and certain viruses, including antibiotic-resistant species is silver. According to Monteiro et al. (MONTEIRO, DR et al. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. International Journal of Antimicrobial Agents, v. 34, p. 103-110, 2009.), silver can be used in reducing infections in burned areas, to prevent bactericidal colonization on medical devices, as well as in textile factories and for water treatment. Silver, as an antiseptic agent, has been effective on a variety of materials, including glass, titanium and polymers.

[06] Um artigo de 2016 publicado no The International Journal Of Molecular Sciences lista propriedades de combate ao câncer como um dos seus usos.[06] A 2016 article published in The International Journal Of Molecular Sciences lists cancer-fighting properties as one of its uses.

[07] Um estudo de 2013 publicado na revista Biomaterials demonstrou que a prata possui propriedades de combate ao câncer, especificamente no tratamento da leucemia.[07] A 2013 study published in the journal Biomaterials demonstrated that silver has cancer-fighting properties, specifically in the treatment of leukemia.

[08] Um estudo de 2010 publicado no Journal of Clinical and Experimental Research concluiu: “...a prata coloidal pode ser um potencial agente alternativo para a terapia de tratamento do câncer de mama em humanos”. Estudos também têm demonstrado benefícios na luta contra o câncer cervical, câncer de fígado e câncer de pulmão.[08] A 2010 study published in the Journal of Clinical and Experimental Research concluded: "...colloidal silver may be a potential alternative agent for human breast cancer treatment therapy". Studies have also shown benefits in fighting cervical cancer, liver cancer and lung cancer.

[09] De acordo com um livro de 2013 intitulado Colloidal Silver, The Natural Antibiotic, a prata coloidal também tem sido usada com sucesso para tratar diarréia, excesso de gases, disfunção da vesícula biliar, mau hálito (Halitose), síndrome do intestino irritável (SCI), conjuntivite, asma, resfriado, acne, queimaduras, caspa e eczema.[09] According to a 2013 book titled Colloidal Silver, The Natural Antibiotic, colloidal silver has also been used successfully to treat diarrhea, excessive gas, gallbladder dysfunction, bad breath (halitosis), irritable bowel syndrome (SCI), conjunctivitis, asthma, cold, acne, burns, dandruff and eczema.

[010] A utilização de cateteres médicos recobertos por fina camada de prata nanométrica, pode impedir a colonização de microrganismos e dessa forma diminuir o tempo de internação hospitalar dos pacientes, pois previne infecções (Jha RK, Jha PK, Chaudhury K, Rana SVS, Guha SK. An emerging interface between life science and nanotechnology: present status and prospects of reproductive healthcare aided by nano-biotechnology. Nano Rev 5:1-19. 2014).[010] The use of medical catheters covered by a thin layer of nanometric silver can prevent the colonization of microorganisms and thus reduce the length of hospital stay of patients, as it prevents infections (Jha RK, Jha PK, Chaudhury K, Rana SVS, Guha SK. An emerging interface between life science and nanotechnology: present status and prospects of reproductive healthcare aided by nano-biotechnology. Nano Rev 5:1-19. 2014).

[011] Astruc et al. (Astruc et al. Nanoparticles as recycable catalysis: the frontier between homogeneous and heterogeneous catalysis. V. 44, p. 7852-7872, 2005) descrevem que as nanopartículas de prata apresentam diversas aplicações como antissépticos, antibacterianos, antifúngicos, etc.[011] Astruc et al. (Astruc et al. Nanoparticles as recyclable catalysis: the frontier between homogeneous and heterogeneous catalysis. V. 44, p. 7852-7872, 2005) describe that silver nanoparticles have several applications such as antiseptics, antibacterials, antifungals, etc.

[012] O mecanismo de ação das nanopartículas de prata não é completamente esclarecido. No entanto, sua atuação resulta em inibição do crescimento e perda da infectividade, ao impedir os processos que ocorrem na superfície e no interior da célula dos microrganismos. A diminuta dimensão da nanoprata é essencial para sua melhor penetração à membrana celular, podendo assim, prejudicar o funcionamento celular, retardando a velocidade de suas atividades vitais, podendo então, ocasionar danos celulares (SHARMA, V. K.; YNGARD, R. A.; e LIN, Y. Silver nanoparticles: Green synthesis and their antimicrobial activities. Chemistry Department, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901, USA, v. 154, setembro, 2008. P. 83-96.).[012] The mechanism of action of silver nanoparticles is not completely clear. However, its action results in growth inhibition and loss of infectivity, by preventing the processes that occur on the surface and inside the cell of microorganisms. The tiny dimension of the nanosilver is essential for its better penetration to the cell membrane, which can harm cell function, slowing down the speed of its vital activities, and can then cause cell damage (SHARMA, VK; YNGARD, RA; and LIN, Y Silver nanoparticles: Green synthesis and their antimicrobial activities. Chemistry Department, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901, USA, v. 154, September, 2008. P. 83-96.).

[013] As nanopartículas de prata são capazes de invadir as células, interagindo com ligações dissulfeto dos conteúdos de glicoproteína/proteína de microrganismos tais como vírus, bactérias e fungos, ou seja, é nociva às proteínas, e consequentemente afeta negativamente o DNA (dificulta sua replicação) e o RNA (impossibilita sua transcrição) (LARA, H. H.; GARZA-TREVINO E. N.; IXTEPAN-TURRENT L.; e SINGH D. K.; Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds, v. 9, agosto, 2011).[013] Silver nanoparticles are able to invade cells, interacting with disulfide bonds of the glycoprotein/protein contents of microorganisms such as viruses, bacteria and fungi, that is, it is harmful to proteins, and consequently negatively affects the DNA (difficults its replication) and the RNA (prevents its transcription) (LARA, HH; GARZA-TREVINO EN; IXTEPAN-TURRENT L.; and SINGH DK; Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds, v. 9, August, 2011) .

[014] O estado da técnica descreve composições antifúngicas e antibacterianas utilizando nanopartículas de prata para revestimento de materiais ou para aplicação tópica.[014] The state of the art describes antifungal and antibacterial compositions using silver nanoparticles for coating materials or for topical application.

[015] O documento BR102017017682 descreve um processo de obtenção de hidrogel com nanopartículas de prata para aplicação tópica em feridas contaminadas.[015] The document BR102017017682 describes a process for obtaining hydrogel with silver nanoparticles for topical application in contaminated wounds.

[016] O documento BR102013013996 descreve uma formulação antisséptica contendo nanopartículas de prata para antissepsia do canal radicular.[016] The document BR102013013996 describes an antiseptic formulation containing silver nanoparticles for root canal antisepsis.

[017] O documento BRPI0519604 descreve composições à base de prata/água, em que as nanopartículas metálicas estão presentes na água em um nível de aproximadamente 5-40 ppm, e em que a composição manifesta propriedades antimicrobianas significativas.[017] The document BRPI0519604 describes silver/water-based compositions, in which metallic nanoparticles are present in water at a level of approximately 5-40 ppm, and in which the composition manifests significant antimicrobial properties.

[018] No entanto, não é descrito nem sugerido uma composição farmacêutica para administração oral a humanos e animais que ataca uma gama maior de microrganismos, não gera cepas resistentes e ataca bactérias que resistem a antibióticos específicos em virtude de acometer qualquer lugar da célula, ao contrário dos antibióticos que atacam um determinado sítio da bactéria.[018] However, it is neither described nor suggested a pharmaceutical composition for oral administration to humans and animals that attacks a wider range of microorganisms, does not generate resistant strains and attacks bacteria that resist specific antibiotics by virtue of affecting any place in the cell, unlike antibiotics that attack a particular site of the bacteria.

ANTECEDENTES DA INVENÇÃOBACKGROUND OF THE INVENTION

[019] A composição farmacêutica à base de nitrato de prata, objeto da presente patente de invenção, compreende nitrato de prata entre 1 ppm a 1000 ppm (partes por milhão), com tamanho de partícula entre 1nm a 1µm, diluído em um soluto selecionado dentre água purificada, água destilada ou álcool.[019] The pharmaceutical composition based on silver nitrate, object of this patent of invention, comprises silver nitrate between 1 ppm to 1000 ppm (parts per million), with particle size between 1nm to 1µm, diluted in a selected solute among purified water, distilled water or alcohol.

[020] O protocolo de tratamento pode variar de uma dose de 10 ml por semana a cinco doses de 10 ml por dia. Nestas concentrações, o nitrato de prata não causa argiria, pois se converte em outros íons não hidrossolúveis, como cloreto de prata, no suco estomacal.[020] The treatment protocol can range from one dose of 10 ml per week to five doses of 10 ml per day. At these concentrations, silver nitrate does not cause argyria, as it converts to other non-water soluble ions, such as silver chloride, in stomach juice.

[021] A dispersão coloidal obtida consegue permear a membrana celular, prejudicando os processos bacterianos, de forma que a bactéria não consegue se adaptar e desenvolver resistência.[021] The colloidal dispersion obtained is able to permeate the cell membrane, harming bacterial processes, so that the bacteria cannot adapt and develop resistance.

[022] Opcionalmente, é adicionado nitrato de zinco, na concentração de 1 a 50 ppm, a fim de aumentar o potencial bactericida, antiviral, ou antifúngico da solução coloidal.[022] Optionally, zinc nitrate is added, at a concentration of 1 to 50 ppm, in order to increase the bactericidal, antiviral, or antifungal potential of the colloidal solution.

[023] Opcionalmente, o soluto é substituído por um excipiente em forma pastosa a fim de prover uma pomada para aplicação tópica para o tratamento de infecções bacterianas, fúngicas e virais na pele ou em mucosas.[023] Optionally, the solute is replaced by an excipient in pasty form in order to provide an ointment for topical application for the treatment of bacterial, fungal and viral infections in the skin or mucous membranes.

[024] Exemplos de formulações da presente invenção incluem a diluição de 10mg a 100 mg de nitrato de prata em 999,9 ml de água purificada ou destilada. A dosagem recomendada varia de uma a três doses diárias de 10 ml da solução diluída em 200 ml de água filtrada, sendo a posologia dependente da enfermidade, podendo ser administrada por até 90 dias.[024] Examples of formulations of the present invention include the dilution of 10mg to 100mg of silver nitrate in 999.9ml of purified or distilled water. The recommended dosage varies from one to three daily doses of 10 ml of the solution diluted in 200 ml of filtered water, the dosage depending on the disease, and it can be administered for up to 90 days.

[025] O nitrato de prata é convertido para cloreto de prata no estômago, se desloca pela corrente sanguínea e é eliminado via fezes e urina após curto período de tempo.[025] Silver nitrate is converted to silver chloride in the stomach, travels through the bloodstream and is eliminated via faeces and urine after a short period of time.

Claims (3)

COMPOSIÇÃO FARMACÊUTICA À BASE DE NITRATO DE PRATA caracterizado por compreender a diluição em soluto de 1 a 1000 ppm de nitrato de prata com tamanho de partícula entre 1nm a 1µm.PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE characterized in that it comprises the dilution in a solution of 1 to 1000 ppm of silver nitrate with a particle size between 1nm and 1µm. COMPOSIÇÃO FARMACÊUTICA À BASE DE NITRATO DE PRATA, de acordo com a reivindicação 1, caracterizado por compreender nitrato de zinco, na concentração de 1 a 50 ppm.PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE, according to claim 1, characterized in that it comprises zinc nitrate, in a concentration of 1 to 50 ppm. COMPOSIÇÃO FARMACÊUTICA À BASE DE NITRATO DE PRATA, de acordo com a reivindicação 1, caracterizado por substituir o soluto por um excipiente em forma pastosa.PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE, according to claim 1, characterized by replacing the solute by an excipient in pasty form.
BR102019026681-3A 2019-12-13 2019-12-13 PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE BR102019026681A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR102019026681-3A BR102019026681A2 (en) 2019-12-13 2019-12-13 PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102019026681-3A BR102019026681A2 (en) 2019-12-13 2019-12-13 PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE

Publications (1)

Publication Number Publication Date
BR102019026681A2 true BR102019026681A2 (en) 2021-06-22

Family

ID=76920337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102019026681-3A BR102019026681A2 (en) 2019-12-13 2019-12-13 PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE

Country Status (1)

Country Link
BR (1) BR102019026681A2 (en)

Similar Documents

Publication Publication Date Title
JP6010224B2 (en) Method of physical antimicrobial treatment
White An historical overview of the use of silver in wound management
EP2704729B1 (en) Antimicrobial silver and acemannan composition for the treatment of wounds or lesions or burns
EP2707007B1 (en) Antifungal compositions for the treatment of nails
CN102499944B (en) Nanometer silver antibiotic and antiviral compound liquid and its preparation method and products
AU2004287281A1 (en) Disinfecting composition and methods of making and using same
Thangavelu et al. Antimicrobial properties of silver nitrate nanoparticle and its application in endodontics and dentistry: a review of literature
CN108042420B (en) Composition for oral health care and application thereof
US10201563B2 (en) Method of treating sinusitis, including chronic sinusitis
LV13745B (en) Silver/water, silver gels and silver based compositions, and methods for making and using the same
WO2008104076A1 (en) Electrocolloidal silver and echinacea root antimicrobial formulation
CN113440645A (en) Composite lysozyme liquid dressing for wound surface and preparation method thereof
CN111904977A (en) Composition for anti-infection treatment of skin and soft tissue and application thereof
BR102019026681A2 (en) PHARMACEUTICAL COMPOSITION BASED ON SILVER NITRATE
WO2017038872A1 (en) Composition having antifungal activity
JPH11228387A (en) Medicinal composition containing iodine-based antimicrobial agent
CN109876007B (en) Ozone antibacterial and disinfecting gel and preparation method thereof
RU2762506C1 (en) Agent for applying oral and nasal cavities and method for its use as part of complex therapy of infectious and inflammatory diseases of nasal and oral cavities
US20150150908A1 (en) Compositions and methods for treating skin wounds
CN1307881C (en) New use of bactericide H4Ag 206 containing silver and its prepared medicine
RU2737268C1 (en) Cosmetic and / or pharmaceutical composition for treating skin diseases
RU2805656C1 (en) Liquid balm and a method of its preparation
BR112019016560A2 (en) ANTISEPTIC COMPOSITION THAT UNDERSTANDS POLYVINYLPYRROLIDONE AND UNITIOL AND USE OF THE COMPOSITION
CN107982282B (en) Gargle for relieving and treating pharyngitis
CN107998071B (en) Method for improving stability of phenytoin silver and phenytoin silver external preparation

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2712 DE 27-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.